AZN - 'Opting In' To ArQule With Insiders
I usually have at least one development-stage biotech in my portfolio at any given time. But after an unusually disappointing stretch with that usually profitable insider investment theme over the past year, my portfolio became devoid of dev-stage biotech earlier in September.
I have high expectations that ArQule (ARQL) won’t disappoint, however, as this dev-stage biotech recently had constructive clinical results, a balance-sheet enhancing secondary offering, and insiders accumulating ARQL “Significantly,” even though the stock is up over 250% since last December.
ARQL showed up on numerous Daily Ratings Reports in recent months,